Sure Valley Ventures

Sure Valley Ventures is a founder-led venture firm with offices in Dublin and London, focused on applied artificial intelligence and immersive software technologies across Ireland and the United Kingdom. The firm was founded by Barry Downes and operates with a clear thesis about the intersection of AI, software, and emerging compute platforms, deploying capital into early-stage companies whose products sit at that intersection.

The thesis centers on applied AI and immersive technologies, with healthcare software and AI in healthcare as one of several priority sectors. In practice, this includes clinical AI tools, healthcare operations software, AI applications in pharma and life sciences, immersive training and simulation for clinicians, and software that uses AI to compress workflows in regulated industries. The firm prefers companies that are building defensible technology rather than thin layers on top of foundation models, and is comfortable with deeper R&D timelines than a generalist software fund.

Investments are typically at Seed and Series A with checks in the one to five million dollar range. Geographic focus is Ireland and the United Kingdom with selective activity elsewhere in Europe. The fund leads or co-leads at Seed and is willing to follow on into Series A as portfolio companies progress. Sure Valley participates in the Enterprise Ireland and broader UK and Irish co-investment ecosystem, which gives portfolio companies access to public matching capital.

The partnership is built around founder Barry Downes and a small team with backgrounds across enterprise software, AI, and entrepreneurship. Founders should expect engagement that reflects an operator’s perspective on building from Ireland and the UK, including realistic conversations about hiring, commercial expansion to the United States, and managing across multiple jurisdictions.

The practical value of taking Sure Valley capital is the combination of meaningful early checks, sector specialization in applied AI, and a network across the Irish and UK technology ecosystems. Portfolio companies benefit from introductions to enterprise customers, follow-on investors in both markets, and access to the Enterprise Ireland and Innovate UK programs that often co-invest alongside the fund. The fit is strongest for technical founders building defensible AI and software products with credible early traction, particularly in healthcare and enterprise verticals, and weaker for purely consumer-facing health applications or for capital-intensive medical device businesses where Sure Valley’s check size and stage focus do not match the funding pattern. For the right kind of applied AI healthcare company in Ireland or the UK, the firm is a credible early lead that brings real sector knowledge to the table.